Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them. MET-233i is being ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it’s acquiring Metsera, and its portfolio of four medications ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. How ‘The Great Lock In’ can help ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Pfizer, which has struggled in the race for new obesity drugs, said ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

President Trump's new 100% tariff on imported drugs creates a major new risk for the pharma sector. While competitors announce flashy, multi-billion-dollar U.S. investment plans, Pfizer appears vague ...

Pfizer will acquire Metsera in a deal worth $4.9 billion up front and up to $7.3 billion if the acquired assets succeed further. Metsera is developing anti-obesity treatments that could differentiate ...

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates. 10 stocks ...

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings a ...

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...